1992 Volume 45 Issue 1 Pages 33-38
The ameliorating activity of an intestinal disaccharidase inhibitor, AO-128, was evaluated in rats with diabetes of varying severity. Diabetic rats were produced by injecting 120mg/kg streptozotocin (STZ) into 1.5- and 5-day-old neonates. From the age of 9 week, the rats were given AO-128 as a dietary admixture at a dose of 5 mg/100g of diet for 28 days. AO-128 normalized the basal levels of plasma glucose, which were elevated, and both glucose tolerance and insulin response, which were impaired in animals injected with STZ at the age of 1.5 days. On the other hand, animals administered STZ at the age of 5 days showed overt diabetes syndrome including features such as hyperglycemia, hypoinsulinemia, hyperphagia, polydipsia, polyuria and glucosuria. AO-128 partly ameliorated these diabetic symptoms.
